Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Search Archive:
49 hot topic(s) found with the query "Huntington's disease"

What Is Huntington Disease?
R Marcus, JAMA, August 21, 2023 (Posted: Aug 21, 2023 1PM)

Huntington disease is a rare genetic disease that affects movement, thinking, and behavior. Huntington disease results from an abnormal gene that damages cells in the brain. It is an autosomal dominant genetic disorder, meaning that individuals born to a parent with Huntington disease have a 50% chance of developing the disease. Rarely, patients with Huntington disease have a gene variant that developed spontaneously and was not inherited. Huntington disease affects about 11 to 14 people per 100?000 individuals in Europe and North America and is less common in Africa and East Asia.

A pilot evaluation of an 8-week mindfulness-based stress reduction program for people with pre-symptomatic Huntington's disease.
Sarah Velissaris et al. J Community Genet 2023 7 (Posted: Jul 18, 2023 2PM)

People with Huntington’s disease (HD) face difficult emotional and practical challenges throughout their illness, including in the pre-symptomatic stage. There are, however, extremely limited psychosocial interventions adapted to or researched for HD. We adapted and piloted an 8-week mindfulness-based stress reduction (MBSR) program in people with pre-symptomatic HD to determine if the program (i) was feasible and acceptable to participants, (ii) resulted in increased mindfulness understanding and skills, and (iii) led to improved psychological adjustment.

Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives
XG Gonzalez et al, J Pers Med, February 22, 2023 (Posted: Feb 22, 2023 6AM)

Huntington’s disease (HD) is an autosomal dominant progressive brain disorder, caused by a pathological expansion of a CAG repeat that encodes the huntingtin gene. This genetic neurodegenerative rare disease is characterized by cognitive, motor, and neuropsychiatric manifestations. The aim of the treatment is symptomatic and addresses the hyperkinetic disorders (chorea, dystonia, myoclonus, tics, etc.) and the behavioral and cognitive disturbances (depression, anxiety, psychosis, etc.) associated with the disease. HD is still a complex condition in need of innovative and efficient treatment.

The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease
HT Mailbach et al, J Pers Medicine, September 22, 2022 (Posted: Sep 22, 2022 6AM)

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin Andrew et al. Nature medicine 2022 8 (Posted: Aug 09, 2022 6AM)

SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase?2 study established to evaluate pepinemab, a semaphorin?4D (SEMA4D)-blocking antibody, for treatment of Huntington’s disease (HD). The trial enrolled a total of 265?HD gene expansion carriers with either early manifest (EM, n?=?179) or late prodromal (LP, n?=?86) HD, randomized (1:1) to receive 18?monthly infusions of pepinemab (n?=?91 EM, 41?LP) or placebo (n?=?88 EM, 45?LP). Pepinemab was generally well tolerated, with a relatively low frequency of serious treatment-emergent adverse events of 5% with pepinemab compared to 9% with placebo,

Failure of genetic therapies for Huntington’s devastates community- Hopes were high for drugs designed to lower levels of a mutant protein, but development has stalled.
D Kwon, Nature News, May 5, 2021 (Posted: May 06, 2021 0PM)

Two pharmaceutical companies have halted clinical trials of gene-targeting therapies for Huntington’s disease (HD), following the drugs’ disappointing performance. Researchers had hoped that the treatments — known as antisense oligonucleotides (ASOs) — would be a game changer for HD, an incurable genetic condition that affects cognition, behavior and movement. But back-to-back announcements have dealt a crushing blow to those affected by the disease.

Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease
FB Rodrigues et al, Science Trans Med, December 6, 2020 (Posted: Dec 17, 2020 8AM)

Previous studies have shown that mutant HTT (mHTT) and neurofilament light (NfL) concentrations are increased in cerebrospinal fluid (CSF) of patients with HD. We measured mHTT and NfL in CSF of patients with HD over the course of 2 years and show that baseline concentrations were good predictors of clinical progression and brain atrophy.

Informing about genetic risk in families with Huntington disease: comparison of attitudes across two decades.
Pierron Lucie et al. European journal of human genetics : EJHG 2020 Dec (Posted: Dec 14, 2020 8AM)

Predictive genetic testing in Huntington’s disease: should a neurologist be involved?
M Oosterloo et al, Eur J Human Genetics, May 13, 2020 (Posted: May 14, 2020 8AM)

A Second Interview With Dr. Nancy Wexler, 30 Years Later
D Grady, New York Times, March 10, 2020 (Posted: Mar 10, 2020 8AM)

It was a story worth waiting for, and I hope I’ve done it justice. She had thought for years that she had Huntington’s, but had the diagnosis confirmed only recently, through a physical exam by a neurologist. She never did take the genetic test that resulted from her own research.

Association of CAG Repeats With Long-term Progression in Huntington Disease
DR Langbehn et al, JAMA Neurology, August 12, 2019 (Posted: Aug 13, 2019 8AM)

Experimental Drug For Huntington's Disease Jams Malfunctioning Gene
R Harris, NPR, May 9, 2019 (Posted: May 10, 2019 9AM)

Daring to hope
M Wadman, Science, August 23, 2018 (Posted: Aug 24, 2018 2PM)

Huntington’s disease Despite gaps in our understanding of the biology that underlies this neurodegenerative condition, potential treatments are on the horizon.
H Brody, Nature Outlook, May 30, 2018 (Posted: May 31, 2018 8PM)

The first DNA-based genetic test: Huntington’s Disease
E Amsen, TGMI, May 25, 2018 (Posted: May 25, 2018 8AM)

Gene-altering treatments are medicine’s best shot yet against Huntington’s disease
E Mullin, Tech Review, Feb 15, 2018 (Posted: Feb 26, 2018 11AM)

Hope & hype on unpublished Huntington’s Disease trial splashy news
P Knoepfler lab blog, Dec 13, 2017 (Posted: Dec 14, 2017 5AM)

Success! ASO drug reduces levels of mutant protein
J Carroll, HD Buzz, Dec 11, 2017 (Posted: Dec 11, 2017 7PM)

Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.
Connor Bronwen et al. Stem cells (Dayton, Ohio) 2017 Nov (Posted: Dec 11, 2017 9AM)

Huntington’s breakthrough may stop disease
J Gallagher, BBC News, Dec 11, 2017 (Posted: Dec 11, 2017 9AM)

Genetics of Huntington disease.
Nance Martha A et al. Handbook of clinical neurology 2017 3-14 (Posted: Nov 06, 2017 6AM)

Hunt to Stop a Killer
Genome Magazine, Oct 2017 (Posted: Nov 06, 2017 6AM)

1993-2014: two decades of predictive testing for Huntington's disease at the Medical Genetics Unit of the University of Genoa.
Mandich Paola et al. Molecular genetics & genomic medicine 2017 Sep 5(5) 473-480 (Posted: Sep 27, 2017 9AM)

How a genetic test for Huntington’s disease could change our plans for children
N Hectel, Wassau Daily Herald, August 15, 2017 (Posted: Aug 16, 2017 8AM)

What do we know about Late Onset Huntington's Disease?
Chaganti Sai S et al. Journal of Huntington's disease 2017 (2) 95-103 (Posted: Aug 08, 2017 0PM)

Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
Wright Dean J et al. Advances in neurobiology 2017 93-128 (Posted: Aug 08, 2017 0PM)

The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.
Tippett Lynette J et al. Advances in neurobiology 2017 129-161 (Posted: Aug 08, 2017 0PM)

Families bear the burden of this disease in silence. Pope Francis made us into a community
M Gable, Stat News, August 8, 2017 (Posted: Aug 08, 2017 0PM)

Huntington's Disease-Update on Treatments.
Wyant Kara J et al. Current neurology and neuroscience reports 2017 Apr (4) 33 (Posted: Jun 27, 2017 9AM)

REVIEW-ARTICLE Intermediate alleles of Huntington's disease HTT gene in different populations worldwide: a systematic review.
Apolinário T A et al. Genetics and molecular research : GMR 2017 Apr (2) (Posted: Jun 27, 2017 9AM)

A Systematic Review of the Huntington Disease-Like 2 Phenotype.
Anderson David G et al. Journal of Huntington's disease 2017 (1) 37-46 (Posted: May 20, 2017 10AM)

Huntington’s case raises questions about passing gene test results to relatives
C Dyer, BMJ 2017; 357 (Posted: May 20, 2017 10AM)

Modern Genome Editing Technologies in Huntington's disease Research.
Malankhanova Tuyana Bairovna et al. Journal of Huntington's disease 2017 Jan (Posted: Feb 26, 2017 4PM)

Molecular Imaging Markers to Track Huntington's Disease Pathology.
Wilson Heather et al. Frontiers in neurology 2017 11 (Posted: Feb 26, 2017 4PM)

Contribution of Neuroepigenetics to Huntington's Disease.
Francelle Laetitia et al. Frontiers in human neuroscience 2017 17 (Posted: Feb 26, 2017 4PM)

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease- Randomized Clinical Trial
Huntington's Study group. JAMA July 5, 2016 (Posted: Jul 06, 2016 7AM)

Deutetrabenazine effectively treats Huntington’s chorea with minimal side effects
Two minute medicine, July 5, 2016 (Posted: Jul 05, 2016 6PM)

Do you really want to know your medical future?
M. Dahl, CNN, March 8, 2016 (Posted: Mar 10, 2016 9PM)

Support communities involved in disease studies
Nature News, March 8, 2016 (Posted: Mar 09, 2016 9AM)

Songbirds Help Pinpoint Effects of Huntington's Disease
Duke Today, March 7, 2016 (Posted: Mar 09, 2016 8AM)

Pridopidine for the treatment of Huntington's disease.
Shannon Kathleen M et al. Expert opinion on investigational drugs 2016 Feb (Posted: Mar 01, 2016 8AM)

Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
Martinez-Horta Saul et al. Parkinsonism & related disorders 2016 Feb (Posted: Mar 01, 2016 8AM)

Current status of PET imaging in Huntington's disease.
Pagano Gennaro et al. European journal of nuclear medicine and molecular imaging 2016 Feb (Posted: Mar 01, 2016 8AM)

Potential Treatment for Huntington's Disease Enters Clinical Testing
SciCasts Clinical Research, February 29, 2016 (Posted: Mar 01, 2016 8AM)

Huntington disease and the potential of gene silencing
Genomics Education Program, October 26, 2015 (Posted: Oct 27, 2015 10AM)

Genetic Counselling for Predictive Testing in Huntington's Disease in One Centre since 1993. Gender-Specific Aspects of Decision-Making.
Arning Larissa et al. J Huntingtons Dis 2015 4(1) 87-98 (Posted: Sep 09, 2015 11AM)

Predictive genetic testing for Huntington's disease: A journey with a genetic counselor as your guide,
National Society of Genetic Counselors, Jun 18 (Posted: Jun 24, 2015 1PM)

Can We Cure Huntington's Disease?
ricki Lewis, PLoS Blog DNA Science Posts, May 28, 2015 (Posted: Jun 01, 2015 11AM)

Cognitive interventions to enhance neural compensation in Huntington's disease.
Andrews Sophie C et al. Neurodegener Dis Manag 2015 Apr (2) 155-64 (Posted: Apr 23, 2015 8AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP